Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy. 1987

P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, MN 55415.

The antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy were compared in a double-blind study. Supine diastolic blood pressure decreased with pinacidil (n = 14) from 96.5 to 82.6 mmHg (p less than 0.05), after a mean of 8.5 weeks at a mean dose of 64.3 mg/day, and with hydralazine (n = 15) from 101.5 to 94.0 mmHg (p less than 0.05), after 8.3 weeks at a dose of 163.3 mg/day. Renal plasma flow, glomerular filtration rate, and urinary albumin excretion did not change with pinacidil or hydralazine therapy. Neither agent altered plasma renin activity. Supine and upright plasma aldosterone concentrations decreased significantly during pinacidil, but not during hydralazine, therapy. Thus, both pinacidil and hydralazine reduced blood pressure and preserved renal function. During pinacidil therapy, plasma aldosterone concentrations decreased, whereas plasma renin activity did not. The mechanism of this response is unclear.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration

Related Publications

P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
February 1985, The Journal of pharmacology and experimental therapeutics,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
January 1983, Pharmacology,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
March 1985, Clinical pharmacology and therapeutics,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
January 1984, Journal of cardiovascular pharmacology,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
April 1988, The American journal of the medical sciences,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
January 1985, Journal of cardiovascular pharmacology,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
September 1986, Seminars in nephrology,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
January 1988, Drugs,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
August 1984, British journal of clinical pharmacology,
P A Abraham, and C E Halstenson, and G R Matzke, and W F Keane
March 1990, Journal of clinical pharmacology,
Copied contents to your clipboard!